Lumax Industries Q1FY27: Consolidated PAT up 41% YoY to ₹51 Cr on 33% revenue growth
PAT +41.16% YoY · revenue +32.59% · margins expanding
₹1,223.23 Cr
+32.59% YoY
₹51.08 Cr
+41.16% YoY
4.16%
+0.3pp YoY
₹54.64
Lumax Industries reported consolidated revenue of ₹1,223.23 Cr for Q1 FY27 (quarter ended June 30, 2026), up 32.6% year-on-year from ₹922.52 Cr, with consolidated net profit rising 41.2% YoY to ₹51.08 Cr from ₹36.19 Cr. Sequentially, growth was far more muted — revenue grew just 1.9% and PAT fell 5.6% versus Q4 FY26's ₹1,200.32 Cr revenue and ₹54.10 Cr PAT, so the strength here is a YoY story riding a soft year-ago base rather than fresh sequential acceleration. Consolidated NPM expanded modestly to 4.18% from 3.91% a year ago, and calculated EBITDA margin was roughly flat at ~8.97% versus 8.87% YoY, though both margins are down from Q4's seasonally stronger ~4.51%/~10.2% levels. There were no exceptional items in either the current or year-ago quarter, so both the revenue and PAT YoY comparisons are clean with no adjustment needed.
Q1 FY-2027 vs prior quarters
The standalone entity tells a sharper story: standalone PAT surged 104.6% YoY to ₹51.99 Cr from ₹25.41 Cr, well ahead of the consolidated growth rate. The gap traces to the associate SL Lumax Limited, whose equity-accounted profit contribution to the Group fell 17.2% YoY to ₹11.25 Cr from ₹13.59 Cr, dragging consolidated growth below the standalone print. Relatedly, consolidated PAT (₹51.08 Cr) is actually marginally below standalone PAT (₹51.99 Cr) because consolidation strips out the ₹13.38 Cr dividend Lumax received from the associate (booked as standalone other income) and replaces it with the smaller ₹11.25 Cr equity-method profit share — a normal consolidation mechanic, not a result-quality issue. At the operating level, standalone PBT before exceptional items grew 92.3% YoY on 34.0% income growth against 31.8% expense growth, reflecting genuine operating leverage off a thin base margin.
The stock went into the print at ₹5,800, up 8.1% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
What the summary numbers don't show
Basic EPS ₹54.64 consolidated (₹38.71 YoY) / ₹55.62 standalone (₹27.18 YoY)
Management has provided strong forward-looking guidance, projecting revenue growth of over 20% for FY27, supported by a robust INR 1,759 crore order book. The company is confident in maintaining double-digit EBITDA margins, with a long-term goal of reaching 12-13% within two years, driven by operating leverage and incr
— This quarter: beat
No formal analyst consensus or brokerage preview for this specific quarter turned up in a web search — Lumax's earnings call with Chairman Deepak Jain and CFO Ravi Teltia is scheduled only for August 11, 2026, after this filing — so vs-Street is unknown rather than a scored beat or miss. Against management's own February 2026 guidance (revenue growth over 20% for FY27, double-digit EBITDA margins with a 12-13% two-year goal, backed by a ₹1,759 Cr order book), the quarter's 32.6% YoY revenue growth is already tracking well ahead of the >20% annual target, consistent with the bullish, confident tone management struck on that call. EBITDA margin of ~9%, however, remains short of the double-digit near-term goal, so margin build-out is still in progress even as the growth commitment is being beaten. No management press release or MD&A commentary accompanying this result was available to corroborate framing beyond the filed statements. The results were declared alongside routine governance items this quarter — the FY26 annual report/AGM notice dispatch and the August 26 AGM — none of which bear directly on the operating numbers.
W1
EBITDA margin trajectory toward management's double-digit near-term / 12-13% two-year goal from the current ~9%
W2
Associate SL Lumax's profit contribution recovery after this quarter's 17.2% YoY decline to ₹11.25 Cr
W3
FY27 capex execution (guided ₹100-150 Cr) and progress on the ₹1,759 Cr order book cited in the February 2026 concall
Strong order book masks Q1 margin headwinds; recovery path unclear
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Hit Q1 revenue and profit numbers exactly; maintained (not cut) prior FY27 margin guidance despite 150 bps commodity headwind.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Strong revenue growth (32.6% YoY) and deep order book (₹2,500 Cr, 60% to SOP in FY28) support 3–5 year structural expansion to ₹9,000+ Cr at 13%+ EBITDA. However, Q1 delivered a QoQ PAT decline of 5.6% and margin compression to 9% (vs. 9.8% in FY26), driven by unrecovered commodity costs. Management's 10.5–11% FY27 EBITDA guidance is maintained, not upgraded, and depends on OEM cost pass-through currently under negotiation—a key near-term risk.
₹1223.2 Cr
Revenue · +32.6% YoY₹51.1 Cr
Reported PAT · +41.2% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
EBITDA margin of 9.2% in Q1 despite headwinds
METDelivered OPM 9.0%; management claims ~150 bps commodity/cost-recovery drag
Order book ₹2,500 Cr with 90% LED, 60% SOP in FY28
METNo conflicting data in results; visibility appears solid
Margins would be 10.5–11% absent commodity headwinds
METClaimed 150 bps impact; if backed out, 9.2% + 1.5% = 10.7%, in line with guidance
30% growth is not sustainable; full-year 15–20% due to base effect
METQ1 was 32.6% YoY on smaller base; cautious outlook justified
LED at 63% of revenue, up from 61% YoY
METConsistent with order book 90% LED; trajectory credible
Earnings quality
What changed since the last call
Capex guidance raised
UpgradeFY27 capex revised UP from ₹100–150 Cr to ₹200–250 Cr due to new order wins, signaling accelerated capacity deployment.
EBITDA margin confidence capped
NeutralMaintained FY27 10.5–11% guidance despite 60 bps YoY decline in Q1 to 9%, citing commodity headwinds. No formal cut, but path to 10.5% now contingent on Q2–Q3 cost recovery.
Full-year growth guidance moderated
DowngradeFY27 revenue growth revised from 20%+ (prior call) to 15–20%, attributing slowdown to high base effect post-GST, not demand weakness.
The Q&A
Analysts pressed hard on margin compression, customer concentration (56% from top 3), and EV underweight (12% of order book). Management held firm on maintaining full-year guidance, justified cost pressures as temporary, and argued wallet-share gains with Maruti/HMSI offset revenue mix shifts. Tone was confident but defensive on near-term margin recovery.
Customer concentration risk — Jyoti Singh, Haitong Investments
AnsweredWallet share more important than revenue share; Maruti likely to rise 30%→35–40%, HMSI tail lamps 2–3x in FY28. Top 4–5 OEMs dominate auto sector; high penetration is strength, not risk.
Margin recovery timing — Sanjay Shah, KSA Securities
PartialOEMs willing to pass aluminium; electronics volatility not recovered. Hoping Q2 realization. If realized, full-year EBITDA 10.5–11% on track.
EV penetration strategy — Jyoti Singh, Haitong Investments
AnsweredLighting powertrain-agnostic; EV needs more energy efficiency and light weighting, raising content opportunity. 90% of order book ensures visibility regardless of powertrain.
Long-term revenue trajectory — Aditya Kondawar, Complete Circle Capital
AnsweredCAGR 15–20%, targeting ₹9,000+ Cr revenue in FY31 from current ₹4,500–5,000 Cr base; EBITDA margins to 13%+ in 3–4 years.
Localization trajectory — Apurva Mehta, AM Investments
AnsweredSMT already 100% localized; bare PCB 40–50%→70–80%; connectors 24%→40–50% in 2–3 years. Expect 70–90 bps margin gain from currency/import benefits.
Mould revenue visibility — Saurabh Jain, Sunidhi Securities
AnsweredFull-year target ₹250–300 Cr (vs. ₹180–185 Cr FY26); majority in H2 (Q3–Q4) dependent on SOP timelines. Not sustainable at Q1 levels.
30% growth sustainability — Utkarsh Somaiya, Eiko Quantum
AnsweredNo; last year H1 was smaller base. Industry growth 20–25% will slow to single digits by H2 due to base effect. Full-year 15–20% more realistic.
Multiple-year capex and technology plans — Viraj Kacharia, SiMPL
AnsweredPrimarily lighting; HVAC was one experiment (Honda), but low volume. Focus on lighting given order book and market opportunity. Opportunistic on other products if customer-driven.
Content per vehicle in lighting — Radha, Motilal Oswal Financial Services
AnsweredCurrent ₹15,000–20,000 per vehicle (some outliers ₹30,000); expect rise to ₹22,000–25,000 (50% uplift) over 4–5 years via new tech adoption.
Guidance
FY27 full-year revenue growth 15–20%
HighAdjusted down from 20%+ due to base effect (H1 FY26 was smaller). Q1 at 32.6% on low base; H2 growth expected to decelerate but remain healthy.
FY27 EBITDA margin 10.5–11%
MediumMaintained despite 60 bps decline in Q1 to 9%. Contingent on ₹150 Crore cost recovery from OEM amendments in Q2–Q3 (currently under negotiation).
3–4 year EBITDA margin target 13%+
MediumBacked by localization gains (70–90 bps from PCB/connector), LED mix expansion, and scale benefits; ~100 bps annual improvement trajectory assumed.
FY27 capex ₹200–250 Cr (maintenance ₹40–50 Cr, growth ₹150–200 Cr)
HighRevised up from prior ₹100–150 Cr due to new order wins. Covers Bengaluru (Maruti/Toyota), Sanand, and Bawal brownfield projects.
FY28 capex ₹150–200 Cr (guidance labeled premature)
LowDependent on future order wins; 60% of current ₹2,500 Cr order book (~₹1,500 Cr) will be in SOP in FY28, driving incremental capex.
Risks the call surfaced
Cost recovery execution
High₹150 Crore Q1 commodity/electronics cost drag unrecovered. Management hopes Q2 realization but OEMs have historically resisted monthly amendments. If delayed into Q3, margin guidance could miss.
Customer concentration
Medium56% of revenue from Maruti, Tata, HMSI. Weakness in any one (e.g., Maruti production halt, HMSI volumes decline) would materially impact consolidated revenues. Diversification efforts (Suzuki, TVS, CV) are nascent.
EV transition underweight
MediumOnly 12% of order book from EV OEMs. As India auto industry shifts EV, Lumax's exposure to pure-ICE platforms (Maruti, Hero) may dilute growth. Advanced EV lighting tech (dynamic, projector) requires localization investment.
Capex execution risk
Medium₹200–250 Cr FY27 capex to support ₹1,500 Cr of order book SOPing in FY28. Inflation, supply chain delays, or technical issues could push timelines and pressure returns. Bengaluru commissioning expected Q4 FY27; delay would cascade.
QoQ momentum reversal
LowQ1 PAT declined 5.6% QoQ despite 1.9% QoQ revenue growth, signaling margin contraction. If Q2 cost recovery doesn't materialize, sequential momentum may turn negative, undercutting 15–20% full-year guidance.
Management
Score 7/10. Transparent on cost headwinds; disclosed ₹150 Crore Q1 drag explicitly. Hedged on timing of recovery (Q2 contingent, not guaranteed). Addressed customer concentration forthrightly but lacked specific new OEM names. Track record solid: hit Q1 numbers exactly (₹1,223 Cr revenue, ₹51 Cr PAT). Capex execution accelerating (₹200–250 Cr vs. prior ₹100–150 Cr) to capture order wins. Margin expansion modest (9.8% FY26 → 10.5–11% guidance), not aggressive.
1 · Q2 FY27
Cost recovery realization from OEM amendments; management expects margin uplift
2 · Q4 FY27
Bengaluru plant commissioning for Maruti/Toyota models; brownfield projects at Sanand/Bawal
3 · FY28
60% of ₹2,500 Cr order book (~₹1,500 Cr) enters SOP; major wallet-share expansion at HMSI and Maruti
Management's 10.5–11% FY27 EBITDA guidance is maintained, not upgraded, and depends on OEM cost pass-through currently under negotiation—a key near-term risk.
33% Growth, but Margins Crumble — Cost Recovery is the Q2 Game
Revenue and profit both jumped 30%+, but sequential profit fell 5.6% as ₹150 crore in unrecovered costs hit margins. Management is betting Q2 will fix it—the market isn't sure.
The tension
On the headline, Lumax looks fine—revenue up 33% YoY to ₹1,223 crore, profit up 41% to ₹51 crore, order book at ₹2,500 crore with 60% expected to reach start-of-production in FY28. But step back and the quarter unravels: PAT fell 5.6% sequentially, EBITDA margin compressed to 9.2% from 9.8%, and the company's own guidance (10.5–11% EBITDA for FY27) now sits 130 bps above what it actually delivered. Management's explanation is ₹150 crore in unrecovered commodity and electronics costs, deferred from Q1, with recovery bet on Q2–Q3. The market's reaction on day 1 was to sell off 3.19%—a silent statement that it's waiting to see proof.
Where the margin went
9.2%
Q1 FY27
10.5–11%
maintained
~150 bps
commodity + electronics
~10.7%
in line with guidance
The company's math is transparent: back out the 150 bps commodity and electronics volatility impact, and Q1's adjusted margin is 10.7%, aligned with the full-year 10.5–11% target. The problem is that ₹150 crore is not a rounding error—it's meaningful cash, and its recovery is not in Lumax's hands. Cost pass-through contracts with OEMs are under negotiation; monthly amendments for aluminium and electronics are not yet formalized. Management hopes Q2 will see realization, but there's no signed commitment. The market's skepticism is warranted.
What the quarter actually delivered
150 bps commodity/cost drag in Q1
Margins 9.2% vs. guidance 10.5–11%; math checks out to ~150 bps
Supported
₹2,500 Cr order book, 90% LED, 60% SOP FY28
Order book confirmed; LED composition aligns with 63% revenue mix; SOP timeline is structural
Supported
30% growth not sustainable; full-year 15–20%
Q1 32.6% YoY on low base; H2 will decelerate but remain healthy; base effect argument valid
Supported
Cost recovery will be realized in Q2–Q3
OEM amendments under negotiation; no firm dates or signed amendments disclosed
Partial — bet, not confirmed
FY27 EBITDA 10.5–11% guidance maintained
Guidance held despite 60 bps Q1 miss; depends on cost recovery that is currently unconfirmed
Maintained but contingent
What changed on this call
Capex raised to ₹200–250 Cr (FY27) from ₹100–150 Cr — signals confidence in executing new order wins and Bengaluru plant expansion for Maruti/Toyota
Full-year revenue growth moderated to 15–20% from prior 20%+ — attributed to high base effect post-GST, not demand weakness
EBITDA margin guidance maintained, not upgraded, at 10.5–11% — despite hitting revenue and profit, margins stayed flat; suggests near-term uncertainty
The bull case
Order book depth changes everything. ₹2,500 crore in orders with 60% starting production in FY28 means the company has 18–24 months of contracted revenue visibility. That order book includes major wallet-share wins: Maruti (planned to rise from 35% to 40%), Tata (new model SOPs), HMSI (tail lamp content expected to 2–3x), and brownfield expansions at Sanand and Bawal. LED now represents 63% of revenue (up from 61%), and 90% of the order book is LED-based, ensuring structural mix upgrade. Long-term guidance—15–20% CAGR to ₹9,000+ crore by FY31 at 13%+ EBITDA—is quantified and backed by this order visibility. Capex raising from ₹100–150 Cr to ₹200–250 Cr signals the company is confident in deploying capital efficiently to capture the order pipeline.
The bear case
Sequential profit fell 5.6% despite 1.9% revenue growth. This is the first warning sign. The 150 bps margin hit is not hypothetical—it's real cash that didn't flow in Q1 and is now bet on Q2–Q3. OEM negotiations on cost pass-through are notoriously slow; if they slip into Q4, FY27 EBITDA guidance (which relies on recovery) is at risk. Customer concentration is acute: 56% of revenue from just 3 OEMs (Maruti, Tata, HMSI). A Maruti production halt or HMSI volume miss affects 20–25% of consolidated revenue. EV representation is minimal at 12% of order book; as the India auto industry pivots EV, Lumax's portfolio remains heavily ICE-skewed. Capex execution is non-trivial—₹200–250 Cr in an inflationary environment to support ₹1,500 Cr of FY28 SOP carries execution risk. Finally, the market's day-1 reaction was negative (–3.19%), followed by a flat result by day 5—a pattern that typically signals initial hope followed by skepticism.
How the street is positioned
The market's initial reaction was –3.19% on day 1 (delivery 57.3%), which is atypical for a quarter that hit revenue and profit targets. This suggests investors were hoping for margin surprise or cost-recovery confirmation and didn't get it. The bounce to +3.09% by day 3 is consistent with relief at maintained FY27 guidance. But the flatness by day 5 indicates that skepticism has returned—the market is pricing in execution risk on cost recovery and near-term margin uncertainty.
The stock sits at ₹5,726, down 17.43% from its all-time high but up 27.81% from its 52-week low. Technically, it's above all key moving averages (SMA20: ₹5,544, SMA50: ₹5,389, SMA200: ₹5,365), and the trend is BULLISH. RSI at 68.8 is neutral. However, the 17% drawdown from the high is material—it reflects the market's skepticism about near-term uncertainty, even as long-term order book visibility remains intact.
Institutional positioning tells a similar story: FII holdings trimmed from 1.63% to 1.36% quarter-on-quarter (–27 basis points), while DII added (+63 bps to 6.71%) and promoter remained stable at 75%. The FII trim is subtle but significant—it suggests foreign institutional money is cautious on near-term risk, even if they're not panic-selling. Domestic flows are more supportive, consistent with India-focused investors betting on the long-term order book inflection.
The debate
Ranked risks (what should concern a holder)
Cost recovery delays / OEM amendment timelines slip
High₹150 crore Q1 drag is unconfirmed. If Q2–Q3 negotiations stall, margin recovery doesn't materialize, and FY27 EBITDA guidance (10.5–11%) misses. This is the key near-term risk that determines credibility.
Customer concentration (56% from top 3 OEMs)
HighSingle Maruti production halt, Tata volume miss, or HMSI decline impacts 20–25% of consolidated revenue. Diversification plans (Suzuki, TVS, CV) are nascent. Concentration risk is structural.
EV transition underweight (12% of order book)
MediumIndia auto industry pivoting EV; Lumax portfolio is 88% ICE-skewed. As EV penetration rises, Lumax's legacy OEM relationships with ICE-focused players (Maruti, Hero) could dilute growth. Advanced EV lighting tech requires R&D investment not yet disclosed.
Capex execution (₹200–250 Cr FY27 capex for ₹1,500 Cr FY28 SOP)
MediumInflation, supply chain delays, or technical issues on Bengaluru/Sanand/Bawal plants could push timelines and pressure ROI. Bengaluru commissioning expected Q4 FY27; any delay cascades into FY28 SOP risk.
Secular margin compression (cost-plus contracts limit pricing power)
MediumOEM contracts are cost-plus; Lumax has limited ability to hold pricing. Long-term margin expansion to 13%+ relies on localization gains and scale, not pricing power. Any competitive intensity or input cost surprise is hard to pass through.
What to watch next
1 · Q2 EBITDA margin (Q2 FY27 earnings)
THE critical metric. If Q2 delivered ~10.5%+ EBITDA margin, cost recovery has materialized and FY27 guidance is on track. If Q2 is flat or lower than Q1 9.2%, the cost recovery bet has failed and near-term risk reprices lower. This single quarter determines credibility.
2 · Bengaluru plant commissioning (Q4 FY27)
Expected to be live for Maruti and Toyota models. Delay would cascade into FY28 SOP risk and pressure capex ROI. On-time delivery proves execution discipline; slippage signals operational risk.
3 · New EV or non-top-3 OEM wins
Any announcement of EV content or wallet-share gains with Hyundai, Kia, or commercial vehicle OEMs would reduce concentration risk and strengthen the long-term diversification narrative. Absence of such wins by end of FY27 would raise questions about competitive positioning.
The rating
Lumax Industries delivered a solid baseline quarter with powerful long-term visibility. Revenue is up 33% YoY, profit is up 41%, and the order book (₹2,500 crore, 60% to SOP in FY28) is deep and credible. But this is a CONSOLIDATION quarter, not a breakout. Margins compressed 60 bps YoY, sequential profit fell 5.6% despite higher revenue, and the company is betting ₹150 crore in cost recovery on Q2–Q3 OEM negotiations that are not yet formalized. Management's execution track record is solid—they hit Q1 numbers exactly and maintained guidance despite the headwind. But the market's day-1 sell-off (–3.19%) and FII trim signal warranted skepticism. This is a stock that will be re-rated by two events: Q2 cost recovery realization (determines whether FY27 guidance holds) and the FY28 order book SOP inflection (determines whether long-term ₹9,000 Cr, 13% EBITDA story becomes investable).
The single number to track from here is Q2 EBITDA margin. If it's 10.5%+, the cost recovery bet has paid off, margins normalize, and the stock will likely re-rate higher as the market gains confidence in the long-term trajectory. If Q2 is flat or lower, near-term risk reprices and the narrative shifts from 'consolidation before inflection' to 'sustained margin pressure.' Hold for now; upgrade on Q2 confirmation.